Literature DB >> 16706242

Extramammary Paget's disease resistant to surgery and imiquimod monotherapy but responsive to imiquimod combination topical chemotherapy with 5-fluorouracil and retinoic acid: a case report.

Jian Nan Ye1, David C Rhew, Felix Yip, Leon Edelstein.   

Abstract

Extramammary Paget's disease (EMPD) is an uncommon skin neoplasm that usually affects the elderly population and occurs in the genital, anorectal, or axillary areas. The recommended treatment of EMPD involves surgical excision, including Mohs micrographic surgery; however, surgery is associated with a high rate of recurrence. There have been reports of successful treatment of recurrence with monochemotherapy involving topical imiquimod 5% cream. We report a case of EMPD recurrence after surgery that was resistant to imiquimod monotherapy but that completely resolved after imiquimod was combined with topical 5-fluorouracil (5-FU) and retinoic acid. To our knowledge, this is the first reported case of imiquimod combination therapy with 5-FU and retinoic acid for the treatment of recurrent EMPD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706242

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  3 in total

Review 1.  A primer on extramammary Paget's disease for the urologist.

Authors:  Joon Yau Leong; Paul H Chung
Journal:  Transl Androl Urol       Date:  2020-02

2.  Long-term functional and quality of life outcomes of patients after repair of large perianal skin defects for Paget's and Bowen's disease.

Authors:  Alissa Conklin; Imran Hassan; Heidi K Chua; E Dawn Wietfeldt; Dirk R Larson; Kristine A Thomsen; Sanhat Nivatvongs
Journal:  J Gastrointest Surg       Date:  2009-02-18       Impact factor: 3.452

3.  Topical Combination of Fluorouracil and Calcipotriene as a Palliative Therapy for Refractory Extramammary Paget Disease.

Authors:  Gabriel E Molina; Saami Khalifian; Jamie L Mull; Lu Chen; Ilana S Rosman; Beverly E Faulkner-Jones; Kenneth H Ngo; Shadmehr Demehri; Lynn A Cornelius; Peggy A Wu
Journal:  JAMA Dermatol       Date:  2019-05-01       Impact factor: 10.282

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.